- Home >
- Clinicals Trials >
- EVOKE-SCLC-04 - (GS-US-600-6165)
Back to clinical trials listLung cancer
EVOKE-SCLC-04 - (GS-US-600-6165)
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (EVOKE-SCLC-04).
- Open at Paris since : 24/07/2025
- Target : Adult
- Phase : Phase III
Trial description
To compare the effect of sacituzumab govitecan (SG) to standard of care (SOC) on Objective Response Rate (ORR) as assessed by blinded independent central review (BICR) per RECIST v1.1.;To compare the effect of SG to SOC on Overall Survival (OS).;Primary Endpoints:;ORR: Percentage of participants with complete or partial response per BICR using RECIST v1.1.;OS: Time from randomization to death from any cause
Url of the trialMain investigator
